2026 IPO Market Hits 100 Deals: What’s Driving the Revival
The U.S. IPO market has completed 100 deals in 2026, running 6% ahead of last year’s pace. Biotech and defense tech are leading first-day pops. Here’s what’s fueling the rebound.
biotech
Pharma Giants Race to Harness AI — What It Means for Drug Stocks
From protein folding to clinical trials, AI is transforming drug discovery. Novo Nordisk’s OpenAI deal is the latest signal for pharma investors.
Revolution Medicines Soars 39% on Pancreatic Cancer Breakthrough
Revolution Medicines’ daraxonrasib nearly doubled survival in a Phase 3 pancreatic cancer trial, sending shares up 39% and reigniting biotech M&A speculation.